← All stocks

Eton Pharmaceuticals, Inc.

ETON Net selling
CIK 0001710340 #2154 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$10.67M
$0.00 on a plan · $4.58M straight out of an exercise
Sold at will
$6.09M
4 of 8 sales
Net
−$10.67M
−$6.09M against sales at will

By person

8 insiders · 8 transactions
83.3×

Sean E. Brynjelsen holds 83.3 times base salary in stock. $59.37M of shares against $712.43K in salary for 2025.

Salary from the company's own proxy. The shares are what Sean E. Brynjelsen last reported holding, valued at $61.77, the price Common Stock was last bought or sold at on the open market here, on 28 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
BRYNJELSEN SEAN
President & CEO
$6.09M (4)
−$6.09M
961,194
3.36%
$59.37M
−18.2%
MAIER PAUL V
Director
$2.95M (3) scheduled
−$2.95M
59,745
0.2090%
$3.69M
0.0%
Krempa David
Chief Business Officer
$1.63M (1) scheduled
−$1.63M
37,025
0.1295%
$2.29M
−54.5%
Gruber James R.
Chief Financial Officer
213,420
0.7467%
$13.18M
−18.5%
RIEDEL NORBERT G
Director
67,155
0.2349%
$4.15M
Opaleye Management Inc. entity
10% owner
40,000
0.1399%
$2.47M
−65.2%
Erdogan-Trinkaus Ipek
Chief Commercial Officer
2,403
0.0084%
$148.43K
−3.4%
Adams Jennifer McKie
Director
0
0.0000%
$0.00
Insider
Date
Role
Action
Shares
Price
Amount
MAIER PAUL V
28 Aug 2026
Director
Sold after exercise
128
$61.77
$7.91K
MAIER PAUL V
28 Aug 2026
Director
Sold after exercise
13,485
$60.21
$811.93K
MAIER PAUL V
28 Aug 2026
Director
Sold after exercise
36,387
$58.64
$2.13M
Krempa David
24 Aug 2026
Chief Business Officer
Sold after exercise
25,000
$65.07
$1.63M
BRYNJELSEN SEAN
20 Aug 2026
President & CEO
Sell
7,342
$62.12
$456.09K
BRYNJELSEN SEAN
20 Aug 2026
President & CEO
Sell
36,373
$61.11
$2.22M
BRYNJELSEN SEAN
20 Aug 2026
President & CEO
Sell
47,307
$60.17
$2.85M
BRYNJELSEN SEAN
19 Aug 2026
President & CEO
Sell
8,978
$62.65
$562.47K

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 4
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 75,000
History held since 15 Nov 2018